Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOWLVG)

Drug Name
Nitazoxanide Drug Info
Synonyms
Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide
Therapeutic ClassAntiparasitic Agents
Cross-matching ID
PubChem CID
41684
ChEBI ID
CHEMBL1401
CAS Number
CAS 55981-09-4
TTD Drug ID
D08EBN
ACDINA Drug ID
D00473

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cytokine-cytokine receptor interaction 2.15 0.00e+0 246/295 (83.39%) CXCL13;CXCL9;IL32;...
Viral protein interaction with cytokine and cytokine re... 2.09 0.00e+0 84/100 (84%) CXCL13;CXCL9;TNFRSF10B;...
TNF signaling pathway 2.04 0.00e+0 103/112 (91.96%) JAG1;LIF;MMP14;...
Osteoclast differentiation 2.00 0.00e+0 117/127 (92.13%) RELB;SQSTM1;FOSL2;...
Mitophagy 1.90 1.22e-2 56/68 (82.35%) SQSTM1;BCL2L1;EIF2AK3;...
Hypertrophic cardiomyopathy 1.90 1.02e-2 81/90 (90%) ITGB4;TTN;ATP2A2;...
Proteoglycans in cancer 1.88 8.74e-3 172/205 (83.9%) MET;FN1;CDKN1A;...
C-type lectin receptor signaling pathway 1.85 1.68e-2 93/104 (89.42%) RELB;CBLB;IL6;...
AGE-RAGE signaling pathway in diabetic complications 1.83 1.50e-2 97/100 (97%) F3;BAX;FN1;...
Small cell lung cancer 1.82 1.47e-2 90/92 (97.83%) BAX;LAMB3;FN1;...
ECM-receptor interaction 1.81 1.56e-2 80/88 (90.91%) ITGB4;AGRN;LAMB3;...
PI3K-Akt signaling pathway 1.80 1.84e-2 317/354 (89.55%) DDIT4;ITGB4;MET;...
Focal adhesion 1.80 1.79e-2 180/201 (89.55%) ITGB4;MET;LAMB3;...
Other glycan degradation 1.79 1.66e-2 13/18 (72.22%) FUCA1;MAN2B1;AGA;...
Basal cell carcinoma 1.77 2.69e-2 41/63 (65.08%) BAX;BMP2;CDKN1A;...
Pertussis 1.76 2.60e-2 64/76 (84.21%) C1QA;C1QB;IRF8;...
Shigellosis 1.75 2.45e-2 180/246 (73.17%) TNIP1;VDAC1;BAX;...
Toxoplasmosis 1.75 2.31e-2 103/112 (91.96%) HSPA6;LAMB3;BCL2L1;...
Galactose metabolism 1.75 2.25e-2 26/31 (83.87%) AKR1B10;HK2;GAA;...
Primary immunodeficiency 1.75 2.26e-2 33/38 (86.84%) PTPRC;IL7R;BLNK;...
Transcriptional misregulation in cancer 1.71 3.32e-2 158/192 (82.29%) MET;PBX1;FUT8;...
Chemokine signaling pathway 1.71 3.17e-2 163/192 (84.9%) CXCL13;CXCL9;CCR7;...
Fructose and mannose metabolism 1.70 3.09e-2 30/33 (90.91%) AKR1B10;HK2;PFKFB3;...
Neurotrophin signaling pathway 1.70 3.11e-2 107/119 (89.92%) BAX;RPS6KA2;IRS1;...
Amoebiasis 1.69 3.23e-2 99/102 (97.06%) LAMB3;FN1;ACTN4;...
Leishmaniasis 1.69 3.30e-2 67/77 (87.01%) NCF4;ITGB1;IL1A;...
Bacterial invasion of epithelial cells 1.68 3.28e-2 59/77 (76.62%) MET;FN1;PTK2;...
PPAR signaling pathway 1.68 3.17e-2 66/74 (89.19%) FABP7;FABP5;SCD;...
Dilated cardiomyopathy 1.67 3.33e-2 86/96 (89.58%) ITGB4;TTN;ATP2A2;...
ErbB signaling pathway 1.66 3.26e-2 79/85 (92.94%) CBLB;CDKN1A;EGFR;...
RNA degradation -1.60 4.62e-2 53/79 (67.09%) CNOT7;MPHOSPH6;LSM5;...
Homologous recombination -1.65 3.19e-2 35/41 (85.37%) BRCA2;RAD51D;MRE11;...
Diabetic cardiomyopathy -1.71 1.79e-2 162/203 (79.8%) NOS3;NDUFB5;SLC2A1;...
Amyotrophic lateral sclerosis -1.73 1.67e-2 267/364 (73.35%) NUP188;NUP214;DCTN5;...
RNA transport -1.77 1.06e-2 128/186 (68.82%) NUP37;GEMIN4;EIF4G2;...
RNA polymerase -1.81 5.83e-3 23/31 (74.19%) POLR2L;POLR1B;POLR3G;...
Thermogenesis -1.81 6.47e-3 173/232 (74.57%) ATP5F1C;MAP2K3;ATP5MC1;...
Ribosome biogenesis in eukaryotes -1.96 2.43e-3 52/108 (48.15%) MDN1;NXT2;NOL6;...
Huntington disease -2.00 1.85e-3 233/306 (76.14%) ATP5MC1;TUBB;ACTR1A;...
Parkinson disease -2.04 1.08e-3 176/249 (70.68%) NDUFB5;PSMC5;GNAL;...
Cell cycle -2.10 0.00e+0 110/124 (88.71%) E2F1;EP300;CCND1;...
DNA replication -2.16 0.00e+0 34/36 (94.44%) RNASEH2A;POLD2;POLD3;...
Ribosome -2.26 0.00e+0 113/158 (71.52%) MRPL12;RPL35A;RPLP2;...
Spliceosome -2.31 0.00e+0 101/150 (67.33%) EIF4A3;THOC1;PRPF19;...
Oxidative phosphorylation -2.71 0.00e+0 93/133 (69.92%) ATP5F1C;ATP5MC1;ATP6V1G1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H